Cargando…

Walking the tightrope: UCH-L1 as an mTOR inhibitor and B-cell oncogene

Detalles Bibliográficos
Autores principales:	Bedekovics, Tibor, Hussain, Sajjad, Galardy, Paul J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718265/ https://www.ncbi.nlm.nih.gov/pubmed/31497243 http://dx.doi.org/10.18632/oncotarget.27154

Ejemplares similares

A cysteine near the C-terminus of UCH-L1 is dispensable for catalytic activity but is required to promote AKT phosphorylation, eIF4F assembly, and malignant B-cell survival
por: Hussain, Sajjad, et al.
Publicado: (2019)

Walking the tightrope
por: Orloff, Erica, et al.
Publicado: (2004)

UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression
por: Hussain, Sajjad, et al.
Publicado: (2015)

Targeting glutaminase and mTOR
por: Tanaka, Kazuhiro, et al.
Publicado: (2015)

mTOR in cerebrovascular disease
por: Van Skike, Candice E., et al.
Publicado: (2019)

mTOR in Human Diseases
por: Dormond, Olivier
Publicado: (2019)

Lessons from Walking the Medical Distancing Tightrope
por: Jenkins, Ian, et al.
Publicado: (2020)

The tightrope of science, media and politics
Publicado: (2020)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

mTOR Signaling in Metabolism and Cancer
por: Huang, Shile
Publicado: (2020)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Identification and Characterization of Two Novel Oncogenic mTOR Mutations
por: Murugan, Avaniyapuram Kannan, et al.
Publicado: (2019)

Exploiting the mTOR paradox for disease prevention
por: Iglesias-Bartolome, Ramiro, et al.
Publicado: (2012)

EGFR and mTOR as therapeutic targets in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2019)

Age-related mTOR in gynaecological cancers
por: Bajwa, Preety, et al.
Publicado: (2017)

Revisiting mTOR and Epithelial–Mesenchymal Transition
por: Herrerias, Mariana M., et al.
Publicado: (2020)

ROS, Klotho and mTOR in cardiorenal aging
por: Daneshgar, Nastaran, et al.
Publicado: (2020)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

Tightrope walking: A new technique in ankle syndesmosis fixation
por: Petscavage, Jonelle M., et al.
Publicado: (2015)

Walking the Tightrope: Counterproductive Work Behavior as Compensation for Citizenship Demands
por: Spanouli, Andromachi, et al.
Publicado: (2016)

Walking the Tightrope: A Proposed Model of Chronic Pain and Stress
por: Lunde, Claire E., et al.
Publicado: (2020)

Older patients with Hodgkin Lymphoma: Walking the tightrope of efficacy and toxicity
por: Barrett, Aisling, et al.
Publicado: (2023)

Inhibitors of mTOR in aging and cancer
por: Zhavoronkov, Alexander
Publicado: (2015)

Gerosuppression by pan-mTOR inhibitors
por: Leontieva, Olga V., et al.
Publicado: (2016)

mTOR inhibitors in cancer therapy
por: Xie, Jianling, et al.
Publicado: (2016)

mTor Inhibitors for the Treatment of Endometriosis
por: Barra, Fabio, et al.
Publicado: (2018)

Targeting ganglioneuromas with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2021)

Overview of Research into mTOR Inhibitors
por: Mao, Beibei, et al.
Publicado: (2022)

Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
por: Renna, Maurizio
Publicado: (2016)

Mechanistic Target of Rapamycin (mTOR) in the Cancer Setting
por: Murray, James T., et al.
Publicado: (2018)

mTOR Signaling in Cardiometabolic Disease, Cancer, and Aging
por: Das, Anindita, et al.
Publicado: (2017)

mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio
por: Alain, Tommy, et al.
Publicado: (2012)

How do mTOR inhibitors fit in the landscape of treatment for relapsed acute lymphoblastic leukemia?
por: Pinchinat, Ashley, et al.
Publicado: (2022)

mTOR pathway in familial focal epilepsies
por: Ribierre, Théo, et al.
Publicado: (2016)

IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

Monitoring of approved studies: A difficult tightrope walk by Ethics Committees
por: Davis, Sanish
Publicado: (2018)

COVID-19 herd immunity strategies: walking an elusive and dangerous tightrope
por: Brett, Tobias S, et al.
Publicado: (2020)

Walking the tightrope: how rebels “do” quality of care in healthcare organizations
por: Wallenburg, Iris, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_581a4f663kgcls897pnicbmluf